Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Several new oral anticoagulants (NOAC) have been recently studied and approved for the
prevention and treatment of venous thromboembolism (VTE) which includes deep vein …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant.
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …

Introduction: Venous thromboembolism (VTE) is a common disorder. Heparin and vitamin K
antagonists have been the standard treatment for VTE for over 50 years. The development of …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …